Maximal neutropenia during chemotherapy and radiotherapy is significantly associated with the development of acute radiation-induced dysphagia in lung cancer patients

被引:43
作者
De Ruysscher, D.
Dehing, C.
Bremer, R.-H.
Bentzen, S. M.
Koppe, F.
Pijls-Johannesma, M.
Harzee, L.
Minken, A.
Wanders, R.
Hochstenbag, M.
Dingemans, A.-M.
Boersma, L.
van Haren, E.
Geraedts, W.
Pitz, C.
Simons, J.
Wouters, B. G.
Rosier, J.-F.
Lambin, P.
机构
[1] Univ Hosp Maastricht, Dept Radiotherapy, MAASTRO Clin, GROW, NL-6229 ET Maastricht, Netherlands
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI USA
[3] Jolimont Hosp, Dept Radiotherapy & Oncol, La Louviere, Belgium
[4] Univ Hosp Maastricht, Dept Pulmonol, Maastricht, Netherlands
[5] Atrium Med Ctr, Dept Pulmonol, Heerlen, Netherlands
[6] Maasland Hosp, Dept Pulmonol, Sittard, Netherlands
[7] Laurentius Hosp, Dept Pulmonol, Roermond, Netherlands
[8] Sint Jans Hosp, Dept Pulmonol, Weert, Netherlands
关键词
chemotherapy; esophagitis; lung cancer; neutropenia; predictive factors; radiotherapy;
D O I
10.1093/annonc/mdm005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Acute dysphagia is a distressing dose-limiting toxicity after concurrent chemoradiation or high-dose radiotherapy for lung cancer. We therefore identified factors associated with the occurrence of acute dysphagia in lung cancer patients receiving radiotherapy alone or combined with chemotherapy. Patients and methods: Radiotherapy, chemotherapy and patient characteristics were analyzed using ordinal regression analysis as possible predictors for acute dysphagia (CTCAE 3.0) in 328 lung cancer patients treated with curative intent. Results: The most significant association was seen between the maximal grade of neutropenia during chemoradiation and dysphagia, with an odds ratio increasing from 1.49 [95% confidence interval (Cl) 0.63-3.54, P = 0.362] for grade 1-2 neutropenia to 19.7 (95% Cl 4.66-83.52, P < 0.001) for patients with grade 4 neutropenia. Twice-daily schedule, mean esophageal dose and administration of chemotherapy were significant predictive factors. By combining these factors, a high-performance predictive model was made. On an individual patient level, 64% of patients were correctly classified and only 1.2% of patients were misclassified by more than one grade. Conclusions: The maximal neutrophil toxicity during concurrent chemotherapy and radiotherapy is strongly associated with the development of acute dysphagia. A multivariate predictive model was developed.
引用
收藏
页码:909 / 916
页数:8
相关论文
共 29 条
[1]  
[Anonymous], P AM SOC CLIN ONCOL
[2]   Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy [J].
Belderbos, J ;
Heemsbergen, W ;
Hoogeman, M ;
Pengel, K ;
Rossi, M ;
Lebesque, J .
RADIOTHERAPY AND ONCOLOGY, 2005, 75 (02) :157-164
[3]   Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial [J].
Bentzen, SA ;
Saunders, MI ;
Dische, S ;
Bond, SJ .
RADIOTHERAPY AND ONCOLOGY, 2001, 60 (02) :123-135
[4]   Normal tissue effects:: Reporting and analysis [J].
Bentzen, SM ;
Dörr, W ;
Anscher, MS ;
Denham, JW ;
Hauer-Jensen, M ;
Marks, LB ;
Williams, A .
SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (03) :189-202
[5]   From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome [J].
Bentzen, SM ;
Saunders, MI ;
Dische, S .
CLINICAL ONCOLOGY, 2002, 14 (05) :372-381
[6]   Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology [J].
Bentzen, Soren M. .
NATURE REVIEWS CANCER, 2006, 6 (09) :702-713
[7]   Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma [J].
Bradley, J ;
Deasy, JO ;
Bentzen, S ;
El Naqa, I .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (04) :1106-1113
[8]   Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer [J].
Chapet, O ;
Kong, FM ;
Lee, JS ;
Hayman, JA ;
Ten Haken, RK .
RADIOTHERAPY AND ONCOLOGY, 2005, 77 (02) :176-181
[9]   Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Vansteenkiste, J ;
Kester, A ;
Rutten, I ;
Lambin, P .
ANNALS OF ONCOLOGY, 2006, 17 (04) :543-552
[10]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063